Cancer Research Technology Limited (CRT) is the leading oncology focused technology transfer and development company which aims to maximise cancer patient benefit from publicly funded research.

CRT works closely with leading international cancer scientists, institutes and funding bodies to protect and develop intellectual property arising from their research and to establish links with commercial partners. To this end, CRT facilitates the discovery, development, marketing and commercialisation of new cancer therapeutics, vaccines, diagnostics and enabling technologies. The company is well resourced to achieve this, in part, through CRT's Development Laboratories with core competences in molecular and cellular biology, drug discovery, early pharmacology and medicinal chemistry.

CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world.

To view CRT's Company Profile click here.